Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics has announced promising preclinical data from Stanford University showing that their investigational cancer drug, HMBD-002, enhances the efficacy of radiotherapy in treating squamous cell carcinoma of the head and neck (SCCHN). The study, published in Cell Reports, indicates that HMBD-002, a VISTA inhibitor, can significantly improve radiotherapy outcomes by promoting a pro-inflammatory immune response, potentially leading to better patient outcomes. This development could position Percheron as a key player in the oncology field, offering a novel approach to overcoming resistance mechanisms associated with radiotherapy.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases.
Average Trading Volume: 2,368,160
Technical Sentiment Signal: Sell
Current Market Cap: A$8.7M
For detailed information about PER stock, go to TipRanks’ Stock Analysis page.